|Bid||6.45 x 3200|
|Ask||6.61 x 1800|
|Day's Range||6.37 - 6.80|
|52 Week Range||2.14 - 11.10|
|Beta (5Y Monthly)||2.33|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 07, 2021 - May 10, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.33|
Precigen, Inc. (PGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that by mutual agreement Rick Sterling is stepping down from his position as Chief Financial Officer effective April 2, 2021. Precigen has commenced an executive search for a successor with the qualifications to contribute to Precigen's accelerating growth from a clinical stage company to a commercial organization.
Every investor in Precigen, Inc. ( NASDAQ:PGEN ) should be aware of the most powerful shareholder groups. Institutions...